Hold Rating Maintained for Edwards Lifesciences Amidst Positive Developments in Mitral Valve Approval and TAVR Challenges

Leerink Partners analyst Mike Kratky has maintained their neutral stance on EW stock, giving a Hold rating on April 14.

Mike Kratky’s rating is based on the recent developments surrounding Edwards Lifesciences’ SAPIEN M3 mitral replacement valve, which has received CE Mark approval. This approval is seen as a positive step for the company’s Transcatheter Mitral and Tricuspid Therapies (TMTT) business, aligning with expectations for European approval by mid-2025 and U.S. approval in the first half of 2026. The new product is expected to address a segment of mitral regurgitation patients who are not suitable for TEER, complementing the existing PASCAL and EVOQUE devices.
Despite this positive development, Kratky maintains a Hold rating as the company’s U.S. Transcatheter Aortic Valve Replacement (TAVR) business faces challenges due to hospital capacity constraints. While the TMTT business shows promise and is expected to contribute significantly to future sales targets, the TAVR segment remains a key area of concern for investors in the near to intermediate term. Therefore, while the news is incrementally positive, it does not warrant a change in the current rating.

In another report released on April 14, TD Cowen also maintained a Hold rating on the stock with a $75.00 price target.

EW’s price has also changed slightly for the past six months – from $69.630 to $69.870, which is a 0.34% increase.